Press Release

October 22, 2026 To, To, Listing Operation Department Listing Compliance Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1, Block G, Bandra Kurla Dalal Street, Mumbai – 400001 Complex, Bandra (E), Mumbai- 400051 (Scrip Code: 544644) (SYMBOL: CORONA) Dear Sir / Madam, Sub.: Press Release Pursuant to the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release on Good Manufacturing Practice (GMP) Compliance Certification from Brazilian Health Regulatory Agency, ANVISA, Brazil for Company’s OSD manufacturing facility and Hormone manufacturing facility, both located at Bhayla, Ahmedabad. The press release is also being made available on the website of the Company at www.coronaremedies.com. You are requested to take note of the above. Thanking you. Yours faithfully, For CORONA Remedies Limited Chetna Dharajiya Company Secretary and Compliance Officer Encl.: A/a PRESS RELEASE CORONA Remedies receives ANVISA GMP (Brazil) Certification for Bhayla Manufacturing Facility, Reinforcing Its Commitment to “One World, One Quality” Ahmedabad | October 22, 2026 CORONA Remedies Limited, an India-focused pharmaceutical company with a strong presence across Women’s Healthcare, Cardio-Diabetes, Pain Management, and Urology, has received Good Manufacturing Practice (GMP) certification from Brazil’s National Health Surveillance Agency (ANVISA) for its manufacturing facility at Bhayla, Ahmedabad, covering both Oral Solid Dosage (OSD) and Women’s Hormone production lines. This milestone further strengthens CORONA’s manufacturing credentials and reaffirms its commitment to maintaining high standards of quality, compliance, and operational excellence. Reaffirming the Philosophy of “One World, One Quality” While India will remain the company’s primary market, contributing over 96% of its revenue; the ANVISA GMP certification further strengthens its manufacturing credentials. This marks CORONA’s third major GMP accreditation, building on its EU-GMP approvals for the Women’s Hormone and OSD facilities and its EAEU-GMP certification for the OSD facility. Brazil represents one of the largest pharmaceutical markets in Latin America, with an estimated market size of USD 44 billion1, this market presents opportunities for pharmaceutical manufacturers with strong quality systems and regulatory capabilities. Together, these recognitions reflect the company’s continued focus on strengthening quality systems, maintaining regulatory compliance, and fostering a culture of continuous improvement across its manufacturing operations. Commenting on this achievement, Mr. Viral Sitwala, Executive Director, CORONA Remedies Limited, said: “Quality has always been central to the way we work at CORONA Remedies. Our philosophy of ‘One World, One Quality’ reflects our belief that the standards we follow must remain consistent and uncompromised. The ANVISA GMP certification for our Bhayla manufacturing facility is an important recognition of the systems, discipline, and collective efforts that go into maintaining these standards. While India remains our primary market and the focus of our business, such accreditations further strengthen our manufacturing credentials and reaffirm our commitment to quality and compliance. We will continue to strengthen our capabilities and uphold the quality standards that guide everything we do.” 1: Brazil Pharmaceuticals Market Size and Forecast, 2026-34 About CORONA Remedies Limited Founded in 2004, CORONA Remedies Limited is an India-focused pharmaceutical company engaged in the development, manufacturing, and marketing of products across key therapeutic areas, including Women’s Healthcare, Cardio-Diabetes, Pain Management, and Urology. The company has established a strong presence in the Indian pharmaceutical market through its focus on scientific expertise, brand building, manufacturing excellence, and quality-driven operations. Its manufacturing facilities and research capabilities support its commitment to delivering high-quality healthcare solutions. Disclaimer: Certain statements contained in this document may be statements of future expectations and other forward-looking statements that are based on management ‘s current view and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. None of CORONA Remedies Limited or any of its affiliates, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its content or otherwise arising in connection with this document. This document does not constitute an offer or invitation to purchase or subscribe for any shares and neither it nor any part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever. For further information, please contact Company Investor Relations Advisors CORONA Remedies Limited Strategic Growth Advisors Pvt Ltd. CIN No: L24231GJ2004PLC044656 CIN No: U74140MH2010PTC204285 Chetna Dharajiya – Company Secretary Sagar Shroff / Tanay Shah & Compliance Officer Email id: sagar.shroff@sgapl.net / tanay.shah@sgapl.net Tel No: +91 98205 19303 / +91 98333 91899